- Home
- VRNA vs IVZ Comparison
VRNA vs IVZ Comparison
Compare VRNA & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- IVZ
- Stock Information
- Founded
- VRNA 2005
- IVZ 1935
- Country
- VRNA United Kingdom
- IVZ United States
- Employees
- VRNA N/A
- IVZ N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- IVZ Investment Managers
- Sector
- VRNA Health Care
- IVZ Finance
- Exchange
- VRNA Nasdaq
- IVZ Nasdaq
- Market Cap
- VRNA 8.3B
- IVZ 9.9B
- IPO Year
- VRNA 2017
- IVZ 1995
- Fundamental
- Price
- VRNA $106.27
- IVZ $22.11
- Analyst Decision
- VRNA Buy
- IVZ Hold
- Analyst Count
- VRNA 11
- IVZ 16
- Target Price
- VRNA $114.10
- IVZ $19.36
- AVG Volume (30 Days)
- VRNA 1.3M
- IVZ 3.6M
- Earning Date
- VRNA 11-03-2025
- IVZ 10-21-2025
- Dividend Yield
- VRNA N/A
- IVZ 3.81%
- EPS Growth
- VRNA N/A
- IVZ N/A
- EPS
- VRNA N/A
- IVZ 0.93
- Revenue
- VRNA $221,673,000.00
- IVZ $6,153,100,000.00
- Revenue This Year
- VRNA $896.59
- IVZ N/A
- Revenue Next Year
- VRNA $77.56
- IVZ $9.86
- P/E Ratio
- VRNA N/A
- IVZ $23.72
- Revenue Growth
- VRNA N/A
- IVZ 5.83
- 52 Week Low
- VRNA $27.54
- IVZ $11.60
- 52 Week High
- VRNA $106.45
- IVZ $22.78
- Technical
- Relative Strength Index (RSI)
- VRNA 68.40
- IVZ 60.21
- Support Level
- VRNA $106.15
- IVZ $21.59
- Resistance Level
- VRNA $106.42
- IVZ $22.73
- Average True Range (ATR)
- VRNA 0.19
- IVZ 0.44
- MACD
- VRNA -0.17
- IVZ -0.06
- Stochastic Oscillator
- VRNA 76.32
- IVZ 60.29
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of July 2025, the firm had $2.025 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 46% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).